Search Results for: amy

-Featuring Stanley H. Appel, M.D., internationally renowned researcher and neurologist--Webinar to be held Friday, June 11, 2021 at 11:30 a.m. ET- HOUSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that it will host a key opinion leader (KOL) webinar on ALS001, the Companys lead asset for the treatment of amyotrophic lateral sclerosis (ALS), on Friday, June 11, 2021 at 11:30 a.m. Continue reading →

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025 released by MarketQuest.biz is a specialized and in-depth study of the market with a detailed focus on the global market trend analysis. The report aims to provide an overview of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market with detailed market segmentation by component, deployment, organization size, the end-user. The market is scrutinized in terms of market size, market share, status, trends, competitive scenario, and potential growth opportunities with a forecast till 2025 Continue reading →

Overview Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS is often called Lou Gehrig's disease, after the baseball player who was diagnosed with it. Continue reading →

NEW YORK, Dec. Continue reading →

Amyotrophic lateral sclerosis (ALS) is a neurological disease and also termed as Lou Gehrigs disease. The disease affects the motor neurons, which control the action of voluntary muscles, as a result the messages between brain and muscle fibers are blocked. ALS could occur in a person due to genetic inheritance, mutation in gene which encodes enzyme copper-zinc superoxide dismutase coupled with defect in chromosome 9. Continue reading →

Global Amyotrophic Lateral Sclerosis Treatment Market By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease, Wohlfart-Disease), Drug Type (Riluzole and Edaravone (Radicava)), By Distribution Channel (Hospital Pharmacies, and Retail & Online Pharmacies), Treatment type (Chemotherapy, Stem cell therapy) End- User (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends & Forecast to 2026 Get a sample copy of report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-amyotrophic-lateral-sclerosis-treatment-market Few of the major competitors currently working in the amyotrophic lateral sclerosis treatment market are Sanofi (France), Mitsubishi Tanabe Pharma Corporation (Japan), BrainStorm Cell Limited (US), ViroMed Co., Ltd (South Korea), Ionis Pharmaceuticals (US), Genervon Biopharmaceuticals, LLC (US), Biogen (US), ORPHAZYME A/S (Denmark), Orion Pharma (Finland), Kringle Pharma, Inc. (Japan), Aquestive Therapeutics (US), Apotex Inc (Canada), Bausch Health Companies Inc. Continue reading →